Health Condition 1: F01-F99- Mental, Behavioral and Neurodevelopmental disorders
Conditions
Interventions
Intervention1: NIL: NIL
Sponsors
Father Muller Medical College Hospital
Eligibility
Inclusion criteria
Inclusion criteria: Patients taking antipsychotic treatment with any one of the drugs: Olanzapine, Risperidone, Quetiapine, for a minimum period of 6 months to a maximum period of 1 year.
Exclusion criteria
Exclusion criteria: Not on monotherapy with study drugs Patient is a known case of diabetes or dyslipidemia or has a Pretreatment history of diabetes or dyslipidemia. Patients on Lithium, Nortriptyline, Amitriptyline, valproic acid, antidepressants for past 3 months and other psychotropic agents known to affect insulin sensitivity. Those on other non-psychiatric drugs known to cause weight gain, hyperglycemia or dyslipidemia like steroids, diuretics, hyperglycemia producing antiepileptics. Have current substance abuse or dependency disorder.Pregnancy. Any clinically relevant disease (liver, renal or heart disease).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study the adverse effects on metabolic parameters like weight change from baseline, blood glucose level change and triglyceride level change from normal in patients not previously known to have metabolic abnormalities, receiving treatment with either Olanzapine or Quetiapine or Risperidone.Timepoint: Patients will be assessed at that time point when on treatment with the study drugs for a duration of 6 months to 1 year. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the Blood pressure change from baseline in patients receiving treatment with olanzapine or risperidone or quetiapine.Timepoint: Patients will be assessed at that time point when on treatment with the study drugs for a duration of 6 months to 1 year. | — |
Countries
India
Contacts
Public ContactDr Quadros Reshma Ronald
Father Muller Medical College Hospital
Outcome results
None listed